T H Svensson

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs
    T H Svensson
    Department of Physiology, Section of Neuropsychopharmacology, Karolinska Institutet, S 171 77, Stockholm, Sweden
    Brain Res Brain Res Rev 31:320-9. 2000
  2. ncbi Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality
    Torgny H Svensson
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Prog Neuropsychopharmacol Biol Psychiatry 27:1145-58. 2003
  3. ncbi Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex
    L Linnér
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    J Pharmacol Exp Ther 297:540-6. 2001
  4. ncbi Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens
    M M Marcus
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden
    Neuropharmacology 40:482-90. 2001
  5. ncbi Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation
    O Zachrisson
    Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Karolinska Hospital, 171 76 Stockholm, Sweden
    Eur Neuropsychopharmacol 10:355-63. 2000
  6. ncbi Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia
    Olivia Frånberg
    Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz vag 2, 171 77, Stockholm, Sweden
    Psychopharmacology (Berl) 196:417-29. 2008
  7. ncbi Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo
    L Arborelius
    Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden
    Psychopharmacology (Berl) 151:77-84. 2000
  8. ncbi [New possibilities in pharmacological treatment of nicotine dependence]
    B E Hildebrand
    Institutionen för fysiologi och farmakologi, Karolinska Institutet, Stockholm
    Lakartidningen 96:5217-22, 5224. 1999
  9. ncbi Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa
    Amani Eltayb
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Biol Psychiatry 58:337-43. 2005
  10. ncbi Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors
    Björn Schilström
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 32:43-53. 2007

Collaborators

Detail Information

Publications34

  1. ncbi Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs
    T H Svensson
    Department of Physiology, Section of Neuropsychopharmacology, Karolinska Institutet, S 171 77, Stockholm, Sweden
    Brain Res Brain Res Rev 31:320-9. 2000
    ..Moreover, our results indicate that AMPA-receptor antagonists may possess an atypical antipsychotic profile...
  2. ncbi Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality
    Torgny H Svensson
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Prog Neuropsychopharmacol Biol Psychiatry 27:1145-58. 2003
    ....
  3. ncbi Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex
    L Linnér
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    J Pharmacol Exp Ther 297:540-6. 2001
    ....
  4. ncbi Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens
    M M Marcus
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden
    Neuropharmacology 40:482-90. 2001
    ..This experimental model may afford a biochemical means to assess the psychotomimetic liability of NMDA receptor antagonists, a side effect that may reduce their usefulness as neuroprotective agents...
  5. ncbi Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance P) mRNA expression in the rat hippocampal formation
    O Zachrisson
    Department of Clinical Neuroscience, Psychiatry Section, Karolinska Institutet, Karolinska Hospital, 171 76 Stockholm, Sweden
    Eur Neuropsychopharmacol 10:355-63. 2000
    ..These results are consonant to the hypothesis that increased cortical CCK transmission may be beneficial in the treatment of psychosis...
  6. ncbi Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia
    Olivia Frånberg
    Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz vag 2, 171 77, Stockholm, Sweden
    Psychopharmacology (Berl) 196:417-29. 2008
    ..Asenapine is a novel psychopharmacologic agent being developed for the treatment of schizophrenia and bipolar disorder...
  7. ncbi Partial 5-HT1A receptor agonist properties of (-)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo
    L Arborelius
    Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden
    Psychopharmacology (Berl) 151:77-84. 2000
    ..A recent study, however, found that pindolol suppresses the firing rate of central 5-HT cells, suggesting that the compound possesses agonistic activity at 5-HT1A autoreceptors...
  8. ncbi [New possibilities in pharmacological treatment of nicotine dependence]
    B E Hildebrand
    Institutionen för fysiologi och farmakologi, Karolinska Institutet, Stockholm
    Lakartidningen 96:5217-22, 5224. 1999
    ..Nicotine replacement still represents our main drug therapy in smoking cessation programmes, but recent experimental findings may lead to the introduction of novel pharmacological treatments...
  9. ncbi Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa
    Amani Eltayb
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Biol Psychiatry 58:337-43. 2005
    ....
  10. ncbi Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors
    Björn Schilström
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 32:43-53. 2007
    ..These results may have bearing on the enhancement of negative and cognitive symptoms in schizophrenia...
  11. ncbi Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence
    Marie Louise Wadenberg
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Int J Neuropsychopharmacol 10:191-202. 2007
    ....
  12. ncbi Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats
    Charlotte Wiker
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Int J Neuropsychopharmacol 11:845-50. 2008
    ..These data suggest that allosteric potentiation of nAChRs may mediate the antipsychotic-like effect of adjunctive galantamine and provide support for the development of alpha7 nAChR-selective allosteric potentiators for schizophrenia...
  13. ncbi Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat
    Monica M Marcus
    Department of Physiology and Pharmacology, Section for Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Int J Neuropsychopharmacol 8:315-27. 2005
    ....
  14. ncbi Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia
    Kent Jardemark
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Curr Opin Investig Drugs 3:101-5. 2002
    ..This review will discuss the current status of selective dopamine D3 and D4 receptor antagonists for the treatment of schizophrenia...
  15. ncbi Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission
    Monica M Marcus
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 35:1952-61. 2010
    ....
  16. ncbi GABA(B) receptor-mediated modulation of the firing pattern of ventral tegmental area dopamine neurons in vivo
    Sophie Erhardt
    Department of Physiology and Pharmacology, Division of Pharmacology, Karolinska Institutet, 171 77 Stockholm, Sweden
    Naunyn Schmiedebergs Arch Pharmacol 365:173-80. 2002
    ..Physiologically, activation of GABA(B) receptors may subserve a dampening function on VTA DA cell excitability which may counterbalance NMDA receptor-mediated excitation...
  17. ncbi Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs
    Nina Lindblom
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, , 171 77, Stockholm, Sweden
    Naunyn Schmiedebergs Arch Pharmacol 372:182-94. 2005
    ..Furthermore, since the withdrawal syndrome in rats was attenuated by immunisation, the nicotine withdrawal in smokers should not be worsened but may even be ameliorated during a quit attempt...
  18. ncbi Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat
    Love Linnér
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 27:691-8. 2002
    ....
  19. ncbi The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex
    Kent Jardemark
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Stockholm, Sweden
    Int J Neuropsychopharmacol 8:157-62. 2005
    ..Our results support the idea that intense smoking in schizophrenia may represent a form of self-medication with nicotine...
  20. ncbi Nitric oxide is involved in nicotine-induced burst firing of rat ventral tegmental area dopamine neurons
    B Schilström
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Nanna Svartz vag 2, S 171 77 Stockholm, Sweden
    Neuroscience 125:957-64. 2004
    ..By inference, our results provide additional support for the involvement of NO in nicotine dependence...
  21. ncbi Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride
    Amani Eltayb
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, , 171 77, Stockholm, Sweden
    Naunyn Schmiedebergs Arch Pharmacol 372:195-202. 2005
    ..These data support the adjunctive use of topiramate in schizophrenia to ameliorate negative symptoms and suggest that this treatment may increase the efficacy, but not the extrapyramidal side effect liability, of the APDs used...
  22. ncbi Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine
    Kent E Jardemark
    Karolinska Institutet, Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, S 171 77 Stockholm, Sweden
    Synapse 63:913-20. 2009
    ....
  23. ncbi Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms
    Olivia Frånberg
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Nanna Svartz vag 2, 171 77 Stockholm, Sweden
    Psychopharmacology (Berl) 204:251-64. 2009
    ..In this study, we further analyzed the effects of asenapine on dopaminergic, noradrenergic, and serotonergic systems in the rat brain...
  24. ncbi Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex
    Asa Konradsson
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Synapse 60:102-8. 2006
    ..Our findings also suggest that risperidone and clozapine may affect NMDA receptor-mediated neurotransmission differently in the mPFC...
  25. ncbi Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain
    L Linnér
    Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    J Neural Transm 111:127-39. 2004
    ..Hence, NRIs may cause a secondary enhancement of central serotonergic activity by a mechanism separate from 5-HT reuptake inhibition; an effect that may contribute to their clinical antidepressant efficacy...
  26. ncbi Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses
    M M Marcus
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, S-171 77, Stockholm, Sweden
    Eur Neuropsychopharmacol 12:379-86. 2002
    ..Consequently, our results do not support the use of low-dose haloperidol as replacement for atypical APD in the treatment of schizophrenia...
  27. ncbi Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum
    Anna Mattsson
    Department of Neuroscience, Retzius Laboratory, Karolinska Institute, Retzius vag 8, S 171 77 Stockholm, Sweden
    Exp Neurol 208:73-9. 2007
    ..This, in turn, might be of relevance for the pathophysiology of schizophrenia and provides a possible link between cholinergic disturbances and alteration of dopamine transmission...
  28. ncbi Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule
    Torun Malmlöf
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, 171 77 Stockholm, USA
    Exp Neurol 212:538-42. 2008
    ....
  29. ncbi Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
    S H L de Villiers
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Respiration 69:247-53. 2002
    ..Consequently, active immunization may provide long-term protection against initiation of tobacco dependence, an effect that may prove particularly advantageous in relapse prevention...
  30. ncbi Antipsychotic-like effect by combined treatment with citalopram and WAY 100635: involvement of the 5-HT2C receptor
    Amani Eltayb
    Section of Neuropsychopharmacology, Department of Physiology and Pharmacology, Karolinska Institutet, S 171 77 Stockholm, Sweden
    Int J Neuropsychopharmacol 10:405-10. 2007
    ..In summary, treatment with an SSRI/5-HT1A antagonist combination might prove beneficial in psychiatric disorders with psychotic/depressive symptoms...
  31. ncbi Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
    Torun Malmlöf
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Stockholm, Sweden
    Exp Neurol 225:408-15. 2010
    ..D3-L-DOPA may thus represent a novel strategy to reduce the total dose requirement and yet achieve an effective control of parkinsonian symptoms...
  32. ncbi Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure
    Sabina H L de Villiers
    Department of Physiology and Pharmacology, Section of Neuropsychopharmacology, Karolinska Institutet, Nanna Svartz vag 2, S 171 77 Stockholm, Sweden
    Vaccine 28:2161-8. 2010
    ....
  33. ncbi Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors
    Monica Mameli-Engvall
    CNRS URA 2182 Unité Récepteurs et Cognition, Institut Pasteur, 75724 Paris Cedex 15, France
    Neuron 50:911-21. 2006
    ....
  34. ncbi Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
    Patricia S Goldman-Rakic
    Department of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA
    Psychopharmacology (Berl) 174:3-16. 2004
    ..Moreover, working memory deficits can be ameliorated by treatments that augment D(1) receptor stimulation, indicating that this target presents a unique opportunity for the restoration of cognitive function in schizophrenia...